Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB    UNC   BE0003739530

UCB (UNC)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
62.02(c) 62.077(c) 62.06(c) 62.352(c) 62.21(c) Last
130 150 0 0 300 Volume
+2.01% +0.09% -0.03% +0.47% -0.23% Change
More quotes
Financials (€)
Sales 2017 4 300 M
EBIT 2017 922 M
Net income 2017 587 M
Debt 2017 575 M
Yield 2017 1,93%
Sales 2018 4 520 M
EBIT 2018 1 077 M
Net income 2018 715 M
Debt 2018 68,8 M
Yield 2018 2,06%
P/E ratio 2017 18,83
P/E ratio 2018 15,85
EV / Sales2017 2,94x
EV / Sales2018 2,68x
Capitalization 12 061 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
07/27 | 07:00amEarnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
06/15 UCB : Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery
06/14 UCB : New study illustrates large treatment gap in post-fracture care …
06/14 UCB : announces four-year imaging results demonstrating low disease progression ..
06/14 UCB : Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minima..
06/14 UCB : New UCB data demonstrates scientific innovation for immunology patients wi..
06/11 UCB : Research!America - Briefing
06/09 UCB : Research!America - Briefing
06/08 UCB : Transparency notification BlackRock, Inc.
06/02 UCB : Transparency notification
06/02 UCB : Transparency notifications BlackRock, Inc.
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 16
Average target price 66,9 €
Spread / Average Target 7,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB1.36%13 488
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results